Table 5 Presents the correlation between ER, PR, HER2, CK5/6 and EGFR staining and clinicopathological variables
From: Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana
IHC Marker n = 100 (100%) | Age | Tumour size | Histology type | Lymph Node involvement | Tumour grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 > 50 years (n = 80, 64%) |  ≤ 50 years (n = 45, 36%) |  ≤ 5 cm |  > 5 cm | IDC NOS | Other | Yes | No | G1 | G2 | G3 | |
ER, n (%) |  | P = 0.346 | p = 0.596 | p = 0.678 | P = 0.366 | P = 0.003 | |||||
Positive 72 (58%) | Â | Â | Â | Â | 25 (66) | 31 (62) | 8 (28) | ||||
Negative 53 (42%) | 13 (34) | 19 (38) | 21 (72) | ||||||||
PR, n (%) | p = 0.166 | p = 0.1.000 | p = 0.503 | p = 0.154 | p = 0.0012 | ||||||
Positive 41 (33%) | Â | Â | Â | Â | 16 (42) | 17 (34) | 3 (10) | ||||
Negative 84 (67%) | 22 (58) | 33 (66) | 26 (90) | ||||||||
HER2, n (%) | p = 0.495 | p = 0.635 | p = 0.029 | p = 0.789 | p = 0.025 | ||||||
Positive 26 (21%) | 11 (24.4%) | 15 (18.8%) | Â | 24 (25) | 2 (6) | Â | 3 (8) | 15 (30) | 8 (28) | ||
Negative 99 (79%) | 34 (75.6%) | 65 (81.2%) | Â | 71 (75) | 28 (94) | Â | 35 (92) | 35 (70) | 21 (72) | ||
Ki67, n 125 (100%) p = 0.008 | p = 0.009 n = 80 (%) | p = 0.026 n = 45 (%) | p = 0.852 | p = 0.272 | p = 0.275 | p < 0.001 | |||||
 ≤ 14% 64 (51) | 48 (60) | 16 (36) |  |  |  | 32 (85) | 20 (40) | 5 (17) | |||
 > 14% 61 (49) | 32 (40) | 29 (64) |  |  |  | 6 (15) | 30 (60) | 24 (83) | |||
CK5/6, n (%) | Â | p = 1.000 | p = 0.769 | p = 0.252 | p = 0.748 | p = 0.189 | |||||
Positive 16 (42%) | Â | Â | Â | Â | Â | ||||||
Negative 109 (87%) | |||||||||||
EGFR, n (%) | p = 0.844 | Â | p = 0,089 | p = 0.825 | p = 0118 | p = 0.001 | |||||
Positive 42 (34%) | Â | Â | Â | Â | 4 (11) | 20 (40) | 16 (55) | ||||
Negative 83 (66%) | Â | Â | Â | Â | 34 (89) | 30 (60) | 13 (45) | ||||
Molecular subtype classification (n = 125), n (%) | p = 0.017 | Â | p = 0.922 | p = 0.093 | p = 0.696 | p < 0.0001 | |||||
Luminal A 44 (35%) | 36 (45) | 8 (18) | Â | Â | Â | 22 (58) | 12 (24) | 2 (7) | |||
Luminal B 23 (18%) | 11 (14) | 12 (27) | Â | Â | Â | 5 (13) | 14 (28) | 4 (14) | |||
Luminal B HER2 Positive 9 (7%) | 5 (6) | 4 (9) | Â | Â | Â | 2 (5) | 6 (12) | 1 (3) | |||
Triple negative32 (26%) | 18 (23) | 14 (31) | Â | Â | Â | 8 (21) | 9 (18) | 15 (52) | |||
HER2 enriched 17 (14%) | 10 (12) | 7 (16) | Â | Â | Â | 1 (3) | 9 (18) | 7 (24) | |||